Chronic Lymphocytic Leukemia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

B-Cell Chronic Lymphocytic Leukemia ? analysis by stage of development, drug target, mechanism of action (MoA ... - Digital Journal



Digital Journal
 
B-Cell Chronic Lymphocytic Leukemia ? analysis by stage of development, drug target, mechanism of action (MoA ... 
Digital Journal
HTF Market Report released a new research document of 166 pages on industry titled as B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. B-Cell Chronic Lymphocytic ...
Relapsed Chronic Lymphocytic Leukemia (CLL) Market Pipeline Therapeutics 2018 Top Key Players, Drug Profile and ... The Financial
Chronic Lymphocytic Leukemia Therapeutics Market Report 2018: Global Briefing, Competitive Analysis and Forecast ... Talk Daily News

all 6 news articles » 


Genomics in Chronic Lymphocytic Leukemia: Current Research & Future Implications - LWW Journals



Genomics in Chronic Lymphocytic Leukemia: Current Research & Future Implications 
LWW Journals
An initially slow-growing common B-cell malignancy with a variable clinical course, chronic lymphocytic leukemia (CLL) represents the most common hematological neoplasm in the developed world (Hematol Oncol Clin North Am 2013;27(2):173-206). Although ...

and more » 


Current Approaches to Diagnosis and Risk Stratification in CLL - Targeted Oncology



Targeted Oncology
 
Current Approaches to Diagnosis and Risk Stratification in CLL 
Targeted Oncology
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) is a malignancy characterized by the clonal proliferation and accumulation of small, mature-appearing CD5-positive B lymphocytes in the blood, bone marrow, and secondary lymphoid tissues.1 A CLL diagnosis is ...

and more » 


Umbraslisib Shows Early Promise in CLL and Lymphoma - OncLive



OncLive
 
Umbraslisib Shows Early Promise in CLL and Lymphoma 
OncLive
?Preclinically, umbralisib has a very unique profile, selectively inhibiting both PI3K delta and CK1 epsilon, as previously described in our Blood paper,? study investigator Owen A. O'Connor, MD, PhD, professor of medicine and experimental therapeutics ...
Umbralisib: A Promising Therapy for Hematologic Malignancies Cancer Therapy Advisor

all 2 news articles » 


Factors Affecting Prognosis and Treatment in CLL - Targeted Oncology



Targeted Oncology
 
Factors Affecting Prognosis and Treatment in CLL 
Targeted Oncology
In 2008, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) published revised guidelines for the diagnosis and treatment of CLL.6 These revised guidelines acted as an update to the National Cancer Institute sponsored Working Group's ...

and more » 


Umbraslisib Shows Encouraging Early Activity in CLL and Lymphoma - Targeted Oncology



Targeted Oncology
 
Umbraslisib Shows Encouraging Early Activity in CLL and Lymphoma 
Targeted Oncology
?Preclinically, umbralisib has a very unique profile, selectively inhibiting both PI3K delta and CK1 epsilon, as previously described in our Blood paper,? study investigator Owen A. O'Connor, MD, PhD, professor of medicine and experimental therapeutics ...

 


B-Cell Chronic Lymphocytic Leukemia Treatment Market expected to reach revenue size of over XX % million by 2023 - The Financial



B-Cell Chronic Lymphocytic Leukemia Treatment Market expected to reach revenue size of over XX % million by 2023 
The Financial
B-Cell Chronic Lymphocytic Leukemia Treatment Market Research Report has the complete assessment of the latest trends of the B-Cell Chronic Lymphocytic Leukemia Treatment market. The report focuses on the manufacturing challenges that are being faced ...

 


B-Cell Chronic Lymphocytic Leukemia Market Growth and Technologies Research Report - The Financial



B-Cell Chronic Lymphocytic Leukemia Market Growth and Technologies Research Report 
The Financial
?B-Cell Chronic Lymphocytic Leukemia- Pipeline Insight, 2018?offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across B-Cell Chronic Lymphocytic Leukemia development. The report provides ...

 


Combinations Continue to Push CLL Field Forward - OncLive



OncLive
 
Combinations Continue to Push CLL Field Forward 
OncLive
OncLive: Can you discuss the impact of recent combination trials in CLL? Barrientos: We are trying to get deeper responses than what we have seen with regular use of a B-cell receptor signaling agent. Moving forward, data such as from the TAP CLARITY ...

 


FDA Approval Sought for Duvelisib in CLL, Follicular Lymphoma - OncLive



OncLive
 
FDA Approval Sought for Duvelisib in CLL, Follicular Lymphoma 
OncLive
?Oral duvelisib is the first PI3K inhibitor to show efficacy as a monotherapy in a randomized phase III study in patients with relapsed or refractory CLL/SLL. Duvelisib monotherapy has also demonstrated significant clinical activity in patients with ...
At Verastem, Infinity's Former Blood Cancer Drug Heads to FDA Xconomy
Verastem submits US marketing application for lead candidate duvelisib; shares ahead 7% premarket Seeking Alpha

all 5 news articles »